CNS Drugs

Papers
(The TQCC of CNS Drugs is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond106
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies88
Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment84
Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications82
Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination74
Overview of Current Drug Delivery Methods Across the Blood–Brain Barrier for the Treatment of Primary Brain Tumors71
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies71
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status69
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview66
Intranasal Insulin for Alzheimer’s Disease64
Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis49
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome47
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression45
Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analys45
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies44
The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases43
Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis40
Siponimod: A Review in Secondary Progressive Multiple Sclerosis40
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia38
Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies38
A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia38
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication37
Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis37
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study35
Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug–Drug Interactions and Tolerability35
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders35
Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain35
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score33
Methadone for Pain Management: A Pharmacotherapeutic Review32
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia31
Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability30
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)30
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status30
Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review30
Fenfluramine for the Treatment of Dravet Syndrome and Lennox–Gastaut Syndrome30
Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis29
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review28
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches28
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis27
The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update27
Efficacy and Safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing Fiberoptic Bronchoscopy: A Multicenter, Double-Blind, Propofol-Controlled, Randomized, Phase 3 Study27
Non-Dopaminergic Treatments for Motor Control in Parkinson’s Disease: An Update27
A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy26
Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System25
Improving the Delivery of Levodopa in Parkinson’s Disease: A Review of Approved and Emerging Therapies25
Cannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis24
Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)24
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders24
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience23
Exploring the Evidence for Broad-Spectrum Effectiveness of Perampanel: A Systematic Review of Clinical Data in Generalised Seizures23
Inhibitors of Src Family Kinases, Inducible Nitric Oxide Synthase, and NADPH Oxidase as Potential CNS Drug Targets for Neurological Diseases22
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment22
Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment21
Potential Role of Curcumin for the Treatment of Major Depressive Disorder21
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis21
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder20
Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke19
Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer’s Disease19
Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively19
Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs18
Pharmacotherapy to Manage Central Post-Stroke Pain18
Risdiplam: A Review in Spinal Muscular Atrophy18
The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis18
COMT Inhibitors in the Management of Parkinson’s Disease18
Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study17
24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations17
Neurobiology, Functions, and Relevance of Excitatory Amino Acid Transporters (EAATs) to Treatment of Refractory Epilepsy17
Opicapone: A Review in Parkinson’s Disease17
A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Rece17
A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD)16
Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval16
Erythropoietin Improves Poor Outcomes in Preterm Infants with Intraventricular Hemorrhage16
Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy16
Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera® (Dimethyl Fumarate)16
Estimating Risk of Antidepressant Withdrawal from a Review of Published Data16
Treatment Options in Refractory Autoimmune Encephalitis15
Associations of Prescribed ADHD Medication in Pregnancy with Pregnancy-Related and Offspring Outcomes: A Systematic Review15
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder15
Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic?15
Nusinersen: A Review in 5q Spinal Muscular Atrophy15
Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis15
Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program14
Irritability in Mood Disorders: Neurobiological Underpinnings and Implications for Pharmacological Intervention14
Antipsychotics and Risk of Neuroleptic Malignant Syndrome: A Population-Based Cohort and Case-Crossover Study14
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?14
Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study14
Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study14
Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review13
Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease13
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis13
Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis13
Vitamin D Supplementation and Cognition in Adults: A Systematic Review of Randomized Controlled Trials13
0.032989978790283